Evaluating the long-term cost-effectiveness of the COBRA-BPS programme in Pakistan
Open Access
- 1 July 2025
- journal article
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002981
Abstract
Introduction: The Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) programme is a community-based initiative for managing hypertension in rural South Asia. Previous analyses found the intervention more effective but too costly to be considered cost-effective, using a gross domestic product-based threshold cost-effectiveness threshold that overlooked Pakistan’s constrained healthcare resources. Additionally, key benefits, such as avoided cardiovascular events and associated cost savings, were not considered. This study evaluates the long-term cost-effectiveness of the COBRA-BPS programme compared with the standard of care (SoC) in Pakistan. Methods: A Markov model was used to estimate long-term costs and health outcomes, measured in life years and disability-adjusted life years (DALYs). Cost-effectiveness was assessed using incremental cost-effectiveness ratios (ICERs) and net monetary benefit statistics. Thresholds of US$183 (based on Pakistan’s marginal productivity of public health expenditure), US$500 and US$1000 per DALY averted were applied. Sensitivity analyses were conducted to assess robustness. Results: Based on the pooled results, the COBRA-BPS programme incurred higher costs than SoC, with an incremental cost of US$105 and an incremental gain of 0.41 DALYs averted over individuals’ lifetimes, resulting in an ICER of US$252 per DALY averted. Conclusion: COBRA-BPS effectively reduces cardiovascular events but has marginal cost-effectiveness when evaluated against the US$183 per DALY threshold. However, it becomes cost-effective at higher thresholds. Compared with previous analyses, our study found a significantly lower cost per DALY averted, driven by substantial downstream cost savings from avoided cardiovascular events.Keywords
Funding Information
- NIHR Global Health Center (NIHR203248)
This publication has 27 references indexed in Scilit:
- Ischemic Stroke Therapeutics2024
- Global, regional, and national burdens of hypertensive heart disease from 1990 to 2019 :A multilevel analysis based on the global burden of Disease Study 2019Heliyon, 2023
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsClinical Therapeutics, 2022
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019JACC, 2020
- Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision MakersApplied Health Economics and Health Policy, 2019
- A severity index study of long-term prognosis in patients with chronic heart failureLife Sciences, 2018
- Potential health impact and cost-effectiveness of drug therapy for prehypertensionInternational Journal of Cardiology, 2017
- The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to ThoughtValue in Health, 2016
- The Economic Impact Of Hypertension In Health Care System Of PakistanValue in Health, 2014
- Profile for Estimating Risk of Heart FailureArchives of internal medicine (1960), 1999